EUVIMEDEUVIMED entdecken
EvaluationsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture

Laura Monge-Olivares iD, Inmaculada López-Hernández iD, Felipe Fernández-Cuenca iD, Álvaro Pascual Hernández iD, Lorena López-Cerero iD

Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)

DOI: 10.1093/jac/dkag149 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 16.05.2026. Verfasst von Laura Monge-Olivares und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla IBIS, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, SE 41009, Spain. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Gram-Negative Bacteria, Chromatography, Affinity. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union, Ministry of Science, Innovation and Universities, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Carbapenemase-producing Gram-negative bacteria represent a major clinical challenge. Rapid detection and characterization of carbapenemase group is essential for guiding therapy and for infection control. We evaluated the performance of Certest ResisCheck® Carbapenemases, a novel lateral flow immunoassay (LFIA), for detecting the main carbapenemase groups from bacterial culture. Materials and methods A multicentre collection of 351 well-characterized clinical Gram-negative isolates, studied by whole-genome sequencing, was tested using this assay. 57 KPC, 53 NDM, 63 VIM, 68 OXA-48-like, 64 IMP and 100 carbapenem resistant non-carbapenemase producers were included.

Results

The LFIA showed an overall sensitivity of 96.4% and specificity of 100%. The positive predictive value (PPV) was 100%, and the negative predictive value (NPV) was 91.7%. No false-positives or cross-reactions with extended-spectrum β-lactamases (ESBLs) or cephalosporinases were observed either with isolates harbouring multiple carbapenemases. Detection rates for IMP and NDM variants reached 100%. Sensitivity for KPC, OXA-like and VIM was slightly lower (93.0%, 95.6% and 96.8%, respectively). Nine false-negative results were observed: KPC-31 (n = 4), VIM-63 (n = 2) and OXA-1054-producing (n = 3) isolates. Increasing the bacterial inoculum managed to obtain a positive result for KPC-31 and VIM-63, but OXA-1054 remained undetected.

Conclusions

Certest ResisCheck® Carbapenemases is a rapid, accurate, and reliable tool for detecting carbapenemases in clinical settings. While some rare variants may escape detection, its strong performance across diverse bacterial species supports its use as part of routine diagnostics to guide timely antimicrobial therapy and control the spread of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesBacterial ProteinsGram-Negative BacteriaChromatography, AffinitySensitivity and SpecificityHumansRapid Diagnostic TestsGram-Negative Bacterial InfectionsImmunoassayPredictive Value of TestsWhole Genome SequencingAnti-Bacterial Agents

Substanzen

beta-LactamasesBacterial ProteinscarbapenemaseAnti-Bacterial Agents

Autor:innen und Institutionen

  • Instituto de Biomedicina de Sevilla IBIS, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, SE 41009, Spain.
  • Departamento de Microbiología, Facultad de Medicina, Universidad de Sevilla, Seville, SE 41009, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, MA 28220, Spain.
  • Unidad de Microbiología y Enfermedades Infecciosas, Hospital Universitario Virgen, Macarena, Seville, SE 41009, Spain.

ORCID-Profile: Laura Monge-Olivares, Inmaculada López-Hernández, Felipe Fernández-Cuenca, Álvaro Pascual Hernández, Lorena López-Cerero

Förderung

  • European Union
  • Ministry of Science, Innovation and Universities
  • European Regional Development Fund

Zitieren

APA

Monge-Olivares, L., López-Hernández, I., Fernández-Cuenca, F., Pascual Hernández, Á., & López-Cerero, L. (2026). Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag149

Vancouver

Monge-Olivares L, López-Hernández I, Fernández-Cuenca F, Pascual Hernández Á, López-Cerero L. Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag149

BibTeX
@article{MongeOlivares2026,
  author = {Monge-Olivares, Laura and López-Hernández, Inmaculada and Fernández-Cuenca, Felipe and Pascual Hernández, Álvaro and López-Cerero, Lorena},
  title = {Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.1093/jac/dkag149}
}
Kostenlos starten →